| Nov 7 |
InflaRx Q3 2024 Earnings Preview
|
| Oct 31 |
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
|
| Sep 25 |
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
|
| Sep 3 |
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
|
| Aug 27 |
InflaRx Announces Participation in September Investor Events
|
| Aug 8 |
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 8 |
InflaRx GAAP EPS of -€0.24 misses by €0.03, revenue of €6.35M beats by €6.25M
|
| Aug 8 |
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 7 |
InflaRx Q2 2024 Earnings Preview
|
| Aug 1 |
InflaRx to Report Second Quarter 2024 Results on August 8, 2024
|
